Abstract. The 'high mobility group' HMGA protein family consists of four members: HMGA1a, HMGA1b and HMGA1c, which result from translation of alternative spliced forms of one gene and HMGA2, which is encoded for by another gene. HMGA proteins are characterized by three DNA-binding domains, called AT-hooks, and an acidic carboxy-terminal tail. HMGA proteins are architectural transcription factors that both positively and negatively regulate the transcription of a variety of genes. They do not display direct transcriptional activation capacity, but regulate gene expression by changing the DNA conformation by binding to AT-rich regions in the DNA and/or direct interaction with several transcription factors. In this way, they influence a diverse array of normal biological processes including cell growth, proliferation, differentiation and death. Both HMGA1 and HMGA2 are hardly detectable in normal adult tissue but are abundantly and ubiquitously expressed during embryonic development. In malignant epithelial tumors as well as in leukemia, however, expression of HMGA1 is again strongly elevated to embryonic levels thus leading to ectopic expression of (fetal) target genes. HMGA2 overexpression also has a causal role in inducing neoplasia. Besides overexpression of full length HMGA proteins in different tumors, the HMGA genes are often involved in chromosomal rearrangements. Such translocations are mostly detected in benign tumors of mesenchymal origin and are believed to be one of the most common chromosomal rearrangements in human neoplasia. To provide clarity in the abundance of articles on this topic, this review gives a general overview of the nuclear functions and regulation of the HMGA genes and corresponding proteins.
Introduction
Life depends on the ability of a cell to store, retrieve, process and translate the genetic instructions required to make and maintain a living organism. This hereditary information is passed on from a cell to its daughter cells at cell division, and from generation to generation of organisms through the reproductive cells. Large amounts of DNA are required to encode all the information needed to generate the instructions for the development of a multicellular organism. This information needs to be stored within the eukaryotic cell and handled appropriately. The latter is achieved by packaging the enormously long double-stranded DNA molecules into chromosomes, which not only fit readily inside the nucleus but can be easily apportioned between the two daughter cells at each cell division. The complex task of packaging is accomplished by specialized proteins that bind to and fold the DNA, generating a series of coils and loops that provide increasingly higher levels of organization and that prevent DNA from becoming an unmanageable tangle. Amazingly, the DNA is compacted in such an orderly fashion so that the genes contained in the DNA molecules are available when they need to be transcribed or replicated. The chromatin fiber thus not only serves to package the DNA into the nucleus, but also provides a means to control the accessibility of specific sequences to regulatory factors and to potentiate interactions between distant regulatory elements. Most of the cellular processes involving DNA thus have to be considered in the context of chromatin (adapted from ref. 1).
The high mobility group of chromosomal proteins
In eukaryotic chromatin, proteins associate with DNA and condense the molecule into the nucleosomic filament made of the succession of nucleosome core particles linked together by DNA segments. Precise interactions between proteins and DNA in chromatin facilitate the orderly progression of complex processes such as transcription, replication, recombination, and repair. Most of the studies on the structure and function of chromatin have focused on interactions occurring between histones (around which the DNA is wrapped and which are constitutive components of the chromatin) and DNA. It is now clear that besides histones there is a second class of proteins, which are either part of, or associated with, the chromatin fiber. These proteins are referred to as non-histone chromosomal proteins and constitute a heterogeneous class of molecules that play an important role in the structure and function of chromosomes and in the regulation of gene activity.
The high mobility group (HMG) proteins are among the largest and best characterized group of non-histone chromosomal proteins (reviewed in refs. [2] [3] [4] . They are defined as nuclear proteins with a high electrophoretic mobility in polyacrylamide gels, can be extracted from nuclei or chromatin with 0.35 M NaCl, and are soluble in 5% perchloric or tricloroacetic acid. Typically, they have a high content of charged amino acids and a molecular mass <30 kDa. The HMG protein family has been classified into three subfamilies: HMGA, HMGB and HMGN, previously known as HMGI/Y, HMG1/2, and HMG14/17 respectively (5). Each of the subfamilies has a unique protein signature and a characteristic functional sequence motif: the 'AT-hook' for the HMGA family, the 'HMG-box' for the HMGB family, and the 'nucleosomal binding domain' for the HMGN family. Via their respective functional motifs, HMG proteins are able to bind to specific structures in DNA or chromatin in a sequence-independent fashion, since they recognize structure rather than a particular nucleotide sequence. HMG proteins function as architectural elements that modify the structure of their binding partners to generate a conformation that facilitates and enhances various DNA-dependent activities such as transcription, replication, recombination, and repair.
The functional motifs characteristic to these canonical HMG proteins have also been identified in other, mostly nuclear, proteins which are called HMG-motif proteins. It is important to distinguish the HMG-motif proteins from the archetypal HMG proteins. The archetypal HMG proteins are ubiquitous in all the cells of higher eukaryotes, are relatively abundant and bind to the DNA in a sequence-independent fashion (also see above). On the contrary, the HMG-motif proteins are cell-type-specific, not abundant and bind to the DNA in a sequence-specific fashion (3) . This review concentrates on the archetypal HMG protein family, more specifically on members of the HMGA family.
The HMGA genes and corresponding proteins
Over thirty years ago, the high mobility group proteins were discovered as abundant heterogeneous non-histone components of chromatin (6) . In 1983, two new high-mobility group-like proteins were found in HeLa cells (7) . Later, these small DNA-binding proteins were categorized as HMGA proteins and different scientific groups became interested in them.
Two genes and four proteins. The mammalian HMGA family consists of two functional members, HMGA1 and HMGA2 (Fig. 1) . Chromosome mapping studies have located the HMGA1 gene on human chromosome 6 (6p21) and on mouse chromosome 17. The human HMGA1 gene contains eight exons, which are distributed over a region of about 10 kb (8), whereas the mouse hmga1 orthologue contains six exons spanning about 7 kb (9, 10) . On the other hand, the human HMGA2 gene is located at chromosomal band 12q14-15 and contains at least five exons dispersed over a genomic region of ≥160 kb. The mouse hmga2 gene locates at the pygmy locus on chromosome 10 and contains five exons spanning more than 110 kb. Both human and mouse HMGA2/hmga2 genes are much larger than their HMGA1/hmga1 counterparts, mainly because of longer 5' and 3' untranslated regions and because of the extremely long third intron of HMGA2/hmga2.
Alternative splicing of the HMGA1 gene transcript gives rise to three mRNAs encoding HMGA1a (107 amino acids, 11.7 kDa), HMGA1b (96 amino acids, 10.6 kDa) and the more recently identified HMGA1c (179 amino acids, 19.7 kDa) (11) . The HMGA1a and HMGA1b isoforms differ by only 11 amino acids present in HMGA1a but not in HMGA1b and are encoded by the most abundant splice variants of the HMGA1 gene. HMGA1c is produced from the HMGA1 gene by alternative splicing using noncanonical splice donor and acceptor sites. This alternative splicing results in a frameshift so that the two proteins are identical in their first 65 amino acids but differ thereafter.
In normal cells, transcripts from the HMGA2 gene code primarily for the full-length HMGA2 protein (109 amino acids, 12 kDa). HMGA proteins occur widespread in nature and homologues for the mammalian HMGA proteins have been found in yeast, insects, plants and birds, as well as in all mammalian species examined (reviewed in refs. 2 and 4).
HMGA proteins and their unusual structural characteristics.
Amino acid alignment of the four HMGA proteins (Fig. 2) shows that the HMGA2 protein has a high amino acid sequence homology (±55%) with the HMGA1a and HMGA1b proteins, including the presence of three conserved DNAbinding domains, also called AT-hooks (see below). At their C-termini, the HMGA proteins, except for HMGA1c, have a high percentage of negatively charged acidic residues. For both genes, the three independent DNA-binding domains are each located on separate exons, as are the regions coding for the acidic C-terminal domains.
The AT-hook motif is a positively charged stretch of 9 amino acids containing the invariant repeat Arg-Gly-Arg-Pro (R-G-R-P), flanked by other positively charged residues [usually Arg (R) and Lys (K); Fig. 2 ]. With these AT-hooks, the HMGA proteins recognize and bind to AT-rich sequences in the minor groove of B-form DNA. As stated above, they recognize structure, rather than a particular nucleotide sequence. Free in solution, AT-hooks possess little, if any secondary structure. Upon binding to DNA, the AT-hook undergoes a disordered-to-ordered conformational change. A single DNA-binding domain preferentially binds to stretches between four and six base pairs, or approximately half a turn of the double helix (4). Simultaneous binding of two or more AT-hooks to different binding sites in its DNA substrate results in an increase in the strength of interactions of HMGA proteins with DNA (12) . Depending on the number and spacing of AT-rich binding sites in DNA, HMGA proteins can influence the conformation of bound DNA substrates in different ways, and consequently, affect numerous biological effects.
The function of the acidic tail is still not understood. It is believed that the C-terminal tail may be important in modulating protein-protein interactions (13, 14) and could be involved in enhancing transcription factor activity (13) . This latter role is, however, quite controversial, since there also exist examples in which removal of the acidic tail has no influence on enhancing activation of genuine transcription factors (15) .
Interestingly, HMGA1 proteins also have the capacity to bind to certain types of structures formed by non AT-rich DNA sequences. For example, in vitro, the HMGA1 protein as well as its DNA-binding domain(s) alone bind to synthetic four-way junction structures, to non-B-form structures in supercoiled plasmids, and to distorted regions of DNA found on isolated nucleosome core particles (16) (17) (18) .
In addition, HMGA proteins participate in protein-protein interactions and induce structural changes in the bound protein substrates. These interactions are a second way in which the HMGA proteins participate in the regulation of expression of many different genes as will be explained below.
In conclusion, by binding to DNA and proteins, HMGA proteins induce structural changes in the substrates with which they interact. In this way, they act as architectural transcription factors that can influence the expression of many different genes. It should be emphasized again that they do not have intrinsic transcriptional activation capacity (19) . AT-hooks (bold); invariant repeat R-G-R-P (grey box); C-terminal acid tail (red box; italics). The region that is deleted in HMGA1b as compared to HMGA1a (asterisks). The amino acid residues of HMGA1c that differ from HMGA1a (underlined) (adapted from ref. 169 ).
the expression of numerous genes. Via protein-DNA and protein-protein interactions, they influence a diverse array of normal biological processes including cell growth, proliferation, differentiation and death. The mechanisms by which HMGA proteins exert their diverse biological functions will be further discussed.
HMGA proteins and chromosome dynamics
Chromosome condensation. The state of condensation of chromosomes varies dramatically during the various stages of the cell cycle. During mitosis, the chromosomes replicate, condense and are subsequently distributed to the two daughter nuclei. The condensed state of the mitotic chromosomes is important in allowing the duplicated chromosomes to be separated during cell division. In interphase nuclei, the chromosomes are in a more extended state, which allows access to the DNA for the enzymes and other proteins required for gene expression and DNA replication. The eukaryotic cell thus has the ability to vary the packaging of its DNA and uses this during progression through the cell cycle as a mechanism to facilitate the required processes at the various time-points.
It has to be noted that the interior of the nucleus is not a random jumble of its DNA, RNA and protein components. Each chromosome occupies a particular region of the nucleus so that different chromosomes do not become entangled with each other. This organization involves, at least in part, attachments of parts of the chromosomes to sites on the nuclear matrix, called matrix/scaffold associated regions (MARs/SARs). Functionally important are, in this context, the highly AT-rich sequences which have high affinity for the nuclear matrix and accordingly organize genomic DNA into topologically distinct loop domains that are important in transcription. In this regard, SARs often localize in close proximity to gene regulatory sequences, including enhancers (20) .
HMGA1 proteins have been shown to be localized at the AT-rich G/Q-and C-bands as well as to the SARs of human and mouse metaphase chromosomes (21) (22) (23) (24) . These localizations suggest that the HMGA proteins are actively involved in the dynamic changes in chromatin structure that occur during chromosome condensation in the cell division cycle. Indeed, treatment of cells with distamycin -a drug which displaces histone H1 and HMGA1 from SARs and other AT-rich sequences -causes marked decondensation of centromeric heterochromatin and substantial metaphase chromosome elongation, indicating that both histone H1 and HMGA1 are necessary for chromosome condensation (25, 26) . However, it is also in such metaphase chromosomes that both the histone H1 and HMGA1 proteins are maximally phoshorylated by the cell cycle-dependent cdc2 kinase (see below), and most loosely bound to the substrate DNA. It is, therefore, possible that this hyperphosphorylation results in an alteration of binding affinity, hereby allowing association of histone H1 and HMGA1 with other chromatin proteins that are causally involved in DNA compaction (27) .
It is well established that the chromatin in an interphase chromosome is not in the same packaging state throughout the whole chromosome. Some regions are more unfolded and extended than others. In general, chromosome regions that are being transcribed into RNA are more extended, while those that are transciptionally silent are more compact. The most highly condensed form of interphase chromatin is called 'heterochromatin'. It is typically concentrated around the centromere region and at the ends of the chromosomes (telomeres). Like mitotic chromatin, heterochromatin is transcriptionally inactive. Chromatin which can occur in a (variety of) more extended state(s) is called 'euchromatin'. Part of this euchromatin is in a state in which it is either actively being transcribed or easily available for transcription.
The HMGA1 proteins were first reported to be associated with the centromeric heterochromatin and have been proposed, based on their binding to discrete sites in African green monkey α-satellite repeats, to play a role in nucleosomal phasing (28) . It has also been shown that the HMGA1 proteins bind to multiple sites in mouse satellite DNA. Studies using the AT-binding drugs Hoechst 33258 and distamycin A show that these drugs cause an incomplete condensation of centromeric chromatin by competing with the HMGA1 proteins for binding to satellite DNA (26) .
Together, these data point towards an important role for HMGA1 proteins in chromatin dynamics during the cell cycle as well as for regulation of transcription on the level of chromatin condensation.
Inhibition of nucleotide excision repair. The amount of information stored in a cell's DNA is enormous. Each cell not only contains an elaborate machinery for accurately copying this stored information, but also specialized enzymes for repairing DNA, when it becomes damaged. Mutations in DNA may affect the information it encodes. Occasionally, this can benefit the organism in which the mutation occurs. In fact, accumulation of DNA changes over millions of years is generally assumed to constitute the basis for the genetic variation among species and indeed is considered the basis of evolution. It also produces the small variations within the same species that we can easily see in humans and other animals. Mutations may, however, be detrimental, and, in humans reflect thousands of inherited diseases. Mutations that arise in the cells of the body throughout the lifetime of an individual may also cause disease, most notably the many types of cancer.
One example of DNA damaging agents is UV radiation. UV radiation produces stable DNA photoproducts by covalent linkage between adjacent bases. The most abundant forms of these photoproducts are cyclobutane pyrimidine dimers (CPD). CPDs alter DNA structure, causing severe bending of the helical axis. They can obstruct progression of DNA polymerase and can inhibit transcription by blocking RNA polymerase or by interrupting formation of the transcription initiation complex. If these CPDs are left unrepaired they can cause mutations and lead to for example skin cancer (29) . It has been shown by Adair et al that HMGA1 overexpression in human cells inhibits their ability to survive exposure to relatively high doses of UV light and that it also significantly reduces their ability for general genomic nucleotide excision repair. One way in which HMGA1 can hamper nucleotide excision repair is by physically inhibiting access of DNA repair-associated proteins to CPD lesions, by directly binding to the UV-induced lesions (30, 31) . Likewise, HMGA1 proteins might negatively regulate transcription of certain genes that code for repair factors, as is shown for the nucleotide excision repair factors ERCC1 (32), and Xeroderma Pigmentosum Group A (XPA) (33) . The decreased repair activity could also be a result of direct interactions between HMGA1 proteins and repair factors, thereby inhibiting their function.
Regulation of gene transcription in vivo
Chromatin structure and gene regulation. As mentioned above, chromatin structure plays a dominant role in the regulation of gene transcription in eukaryotic cells. Genes which are being expressed seem to be in a more extended form of chromatin, although the DNA is still packaged into nucleosomes. Since nucleosomes are placed along DNA at regular intervals with little apparent sequence specificity, they are likely to occur over promoter regions. In that case, they can inhibit initiation of transcription because they prevent the general transcription factors or RNA polymerase from assembling on the DNA. Also other inhibitory chromatin proteins (e.g. histone H1) can be associated with critical regulatory regions of gene promoters or enhancers. When transcription of a gene is activated, such nucleosomes and other inhibitory proteins are displaced from the DNA. One way of achieving this displacement is by destabilizing the intermolecular binding of histones and other regulatory protein complexes in the vicinity of a promoter by biochemically modifying them. Another way is to have specialized proteins which can displace histones and other regulatory protein complexes from promoters and consequently clear the way for the general transcription factors to assemble. One class of these specialized proteins are the HMGA proteins. HMGA proteins act as regulators of gene transcription by controlling the global structure of large loops or domains of chromatin. Preferential binding of HMGA proteins to the SARs at the base of repressed chromatin loops and concomitant displacement/exclusion of histone H1 from these sequences leads to a local opening of chromatin and initiation of the gene activation process. This initial binding is followed by a cooperative propagation of HMGA binding throughout an entire chromatin domain and the establishment of an accessible structure that is permissive for gene transcription. In this model, the HMGA proteins act as 'anti-repressor' molecules that displace inhibitory proteins from SAR sequences (24) . An example is the proximal promoter region of the human IL-2Rα gene, where stably positioned nucleosomes that occlude important transcription factor binding sites are present on the PRRII regulatory element. The HMGA proteins are proposed to be involved in the initial remodelling of the inhibitory nucleosomes and the subsequent formation of an enhanceosome on this element [(34); also see below].
In this context, it has also been proposed that recruitment of histone acetyl transferases (HATs) by sequence-specific transcription factors, like the retinoic acid receptors (RARs) and retinoid X receptors (RXRs), leads to destabilization of nucleosomal cores by acetylation of core histones. RARs and RXRs are nuclear receptors which induce gene expression in a ligand-dependent manner through RA-responsive elements (RAREs) present in the promoter regions of responsive genes. However, before HATs can acetylate the core histones, the inhibitory linker histone H1 should first be removed. Since HATs do not acetylate the histone H1 in its DNA binding tail, removal of histone H1 has to be achieved in another way. Nagpal et al showed that RARs are capable of recruiting the HMGA1 proteins, which can than displace histone H1. This results in a conversion from the silent 30-nm chromatin fiber to a relatively open 10-nm fiber. In a second step, HAT activities are then recruited, leading to a destabilization of the nucleosomal core and active transcription (11) . These scientists were also the first to describe the existence of a third HMGA1 protein, namely HMGA1c (see above).
Long-range chromatin interactions.
Nearly all eukaryotic promoters require activator proteins to aid the assembly of the general transcription factors and RNA polymerase. The DNA sites to which the eukaryotic gene activators bind are called 'enhancers'. These activator proteins can be bound thousands of nucleotide pairs away from the promoter. To allow the activator proteins bound to the enhancer to come into contact with either RNA polymerase or with one of the general transcription factors bound to the promoter, the DNA between the enhancer and the promoter has to loop out. The HMGA proteins have been proposed to be involved in long-range enhancer-promoter interactions. For example, inducible expression of the chicken ß-globin gene requires a functional interaction between a specialized TATA-box motif located at -30 bp in the gene's 5' promoter and a distal 3' enhancer element located ±1.9 kb downstream of the start of the ß-globin's coding region (35) . Bagga et al demonstrated that HMGA1 proteins mediate chromatin looping and longrange interactions of these widely spread regulatory regions to regulate the chicken ß-globin gene (36) . The HMGA proteins are also implicated in the chromatin remodelling that occurs in the promoter region of the human IL-2Rα gene (37) . Transcriptional activation of the IL-2Rα gene involves more than restructuring of its proximal promoter region, as discussed in the previous section. To effect maximal transcription of the IL-2Rα gene following T-cell activation, distinct gene regulatory regions, which are positioned along a stretch of more than 12 kb of genomic DNA, have to be temporally and coordinately controlled. HMGA1 binding sites are known to be present in all of the known IL-2Rα gene regulatory regions and HMGA1 proteins physically interact with many of the transcription factors involved.
Enhanceosome formation. It is believed that specific gene expression patterns are controlled by massive molecular aggregates termed transcription complexes. These complexes, which assemble over the regulatory region of a gene, are composed of four classes of proteins that together govern the specifity and activity of transcription. The first class of proteins is composed of activators. Activators bind co-operatively to promoters and enhancers to assemble into nucleoprotein complexes called enhanceosomes. The second class of proteins is composed of co-activators, which are recruited to the gene by the enhanceosome. The co-activators then interact with the third class of proteins: general factors such as RNA polymerase, which carry out the catalytic process of transcription initiation and elongation. Co-activators also interact with a fourth class of factors: elements that modify and remodel chromatin. These elements thus assist in enhanceosome assembly by bending DNA to allow the cooperative interactions to occur. Seen the unusual structural characteristics of the HMGA proteins, they could easily fit in this fourth class of proteins.
HMGA proteins are indeed known to be able to orchestrate the regulation of gene expression by altering DNA conformation and recruiting transcription factors to DNA. One of the best-characterized mechanisms of gene regulation in which HMGA1 proteins are involved, is that of the virus inducible enhancer of the human ß-interferon gene [IFN-ß; (38) ]. The DNA-protein complex formed on the IFN-ß promoter serves as a stereo-specific platform involved in recruiting RNA polymerase II and other co-factors necessary for transcription initiation. In its basal configuration, IFN-ß enhancer DNA is in an unfavourable conformation to allow recognition by its cognate transcription factors. However, after viral infection, HMGA1 enhances the interaction of transcription factors (such as NF-κB, ATF-2/c-jun, and IRF-1/3/7) with their binding sites by adhering to AT-rich sequences and so reversing the curvature of the DNA. HMGA1 proteins also engage in protein-protein interactions with the bound transcription factors, thereby stabilizing the enhanceosome (also see above). In a next step, the transcriptional coactivator complex GCN5/PCAF and the RNA polymerase II are recruited to complete the complex assembly process of the massive molecular aggregate resulting in the initiation of transcription. A similar mechanism is seen in the HMGA1-dependent regulation of NOS2 (39) .
Protein-protein interactions. As discussed above, HMGA proteins are known to regulate transcription of many genes by binding to DNA and hereby altering the structure of the DNA, allowing cooperative recruitment of gene activators. Together with the HMGA proteins, these activators assemble into a higher order nucleoprotein complex, called the enhanceosome. Indeed, the assembly and function of the enhanceosome requires a complex network of protein-DNA and proteinprotein interactions as is shown for the IFN-ß gene. These protein-protein interactions involve binding between HMGA proteins and other nuclear proteins, most of which are transcription factors (reviewed in refs. 4 and 40) . Upon binding, HMGA proteins induce structural changes in their bound protein substrates. Different transcription factors interact with different parts of the HMGA proteins. These interaction sites are distributed along their entire length. Some of the transcription factors interact with large areas of the HMGA proteins [e.g. ATF-2/c-Jun (13)], while others interact with a much more restricted portion. In any case, the site of interaction includes part, or the whole, of one or more AT-hook motifs, plus flanking regions. The region between the second and third AT-hook of the HMGA1 protein, for example, has the most identified interacting partners. The NF-κB p50 subunit is known to interact with this region in both the HMGA1 and HMGA2 proteins (14) . The transcriptional repressor p120 E4F also interacts with HMGA2 via this region (41) .
Via direct protein-protein interactions with transcription factors, HMGA proteins can also influence gene transcription without first binding to DNA. HMGA1, for example, is able to enhance binding of serum response factor (SRF) to DNA by interacting with SRF, leading to SRF-dependent transcription (15) . HMGA2, on the other hand, can for example interact with the E1A-regulated transcriptional repressor p120
E4F . This interaction results in disruption of p120 E4F binding to the cAMP response element (CRE) site of the promoter and subsequent activation of cyclin A gene transcription (41) .
Virus integration and expression. From the above, it is clear that the HMGA proteins are implicated in a wide range of cellular processes including chromosome changes during the cell cycle, chromatin remodelling, regulation of cellular gene transcription, DNA replication, and DNA repair. In addition, the HMGA proteins also seem to be important in integration of retroviruses into host genomes, as well as viral gene transcription. The HMGA proteins have been shown to act as co-factors in the infectious process of HIV-1 (42), Moloney murine leukemia virus (MoMuLV) (43, 44) , and avian sarcoma virus (ASV) (45) by facilitating integration of double stranded linear cDNA copies of their genomes into host cell chromosomes (46, 47) . HMGA proteins appear to be associated with pre-integration complexes (PICs). It has been proposed by Li et al that binding of monomeric HMGA proteins to multiple AT-rich sites on retroviral cDNAs in PICs leads to DNA compaction and the formation of active integrase-cDNA complexes (43) . The HMGA proteins are also employed as host cell-supplied factors involved in controlling transcriptional expression of a number of viral genes. They bind to AT-rich regions of viral promoter/enhancer regions and, in cooperation with both viral copies and host proteins, control viral gene transcription. Examples include regulation of the early and late genes of the human JC papovavirus (48); the IE-3 gene (which codes for the immediate early protein ICP4) and the latency active promoter (LAP-2) of herpes simplex virus-1 (HSV-1) (49); and the human papillomavirus type 18 (HPV18) oncogenes (50, 51) . In these examples, HMGA1 is involved in the formation of the enhanceosome to activate transcription. HMGA1 can also cooperate with the chromatin remodelling complex (the hSWI/SNF complex), which is situated in the 5' long terminal repeat (LTR) promoter/enhancer of the human HIV-1 virus (52).
The role played by the HMGA proteins in retroviral integration and viral gene transcription mechanistically mimics the normal function(s) of these proteins in eukaryotic cells.
Effect of post-translational modifications. The HMGA proteins are among the most highly adducted proteins in the nucleus, exhibiting complex patterns of phosphorylations, acetylations, methylations and possibly other modifications [e.g. sumoylation (53), ribosylation (54)]. It is obvious that these secondary biochemical modifications may profoundly alter the affinity of HMGA proteins to bind to both DNA and proteins and consequently affect their biological activities. Most studies regarding post-translational modifications have focused on the HMGA1 protein, which will therefore be discussed in more detail (also see Fig. 3 ).
With regard to phosphorylation, HMGA proteins are amongst the most highly phosphorylated proteins in the nucleus. For example, as mentioned in the part about the role of HMGA proteins and chromatin structure, cdc2 kinase phosphorylates the HMGA1 proteins on specific amino acid residues in the G2/M phase of the cell cycle. This phosphorylation clearly reduces the affinity of binding of the HMGA proteins to DNA (27) . HMGA1 proteins are also downstream targets of a number of signalling pathways that originate from receptor molecules on the cell surface. Two well studied examples of the intimate connection between events occurring at the cell surface and the state of phosphorylation of HMGA proteins in the cell nucleus are modifications resulting from the activation of casein kinase 2 (CK2) and protein kinase C (PKC In addition to phosphorylation, HMGA proteins are subjected to acetylation at a number of sites. Acetylation, like phosphorylation, of HMGA proteins serves a specific regulatory function. As discussed above, the HMGA1 protein is involved in virus-induced expression of IFN-ß. After formation of the enhanceosome, the GCN5/PCAF complex is recruited that acetylates Lys 71 of HMGA1, hereby stabilizing the enhanceosome. Later, the CBP/p300 acetyl transferase acetylates Lys 65 of HMGA1, which results in a destabilization and disassembly of the enhanceosome, leading in turn to transcriptional turn-off of the human IFN-ß gene (60) (62) . It has recently been demonstrated that HMGA1 proteins also undergo methylation. Examples include Arg 24 within the first AT-hook of HMGA1a, which has been found methylated in tumor cell lines. Methylation of this residue appears to be modulated during apoptosis, reaching highest levels at later stages of the apoptotic process (63) . Dimethylation of arginine and lysine residues on both HMGA1a and HMGA1b was found to be increased in breast cancer cells with higher metastatic potential (64, 65) . Sgarra et al identified HMGA1a as a target of the protein arginine methyltransferase PRMT6, which specifically methylates HMGA1a on Arg 56 and Arg 58 within the second AT-hook domain (66) . This region has been shown to have the highest affinity for DNA binding and also to be involved in protein-protein interaction. Arginine methylation in this region thus probably plays an important role in HMGA functions. All findings on methylation of the HMGA1 proteins on different Arg residues were very recently confirmed and extended by Zou et al (67) .
Differential functions for HMGA1a, HMGA1b and HMGA2?
The HMGA family members, being HMGA1a/b/c and HMGA2, posess a very high sequence homology (Fig. 2) . The HMGA1a and HMGA1b proteins are nearly identical in amino acid sequence, the only difference being an internal deletion of 11 amino acids, as stated above. Therefore, one might ask the question to which extent they control the expression of the same set of genes. It is clear that the HMGA proteins are indeed able to regulate transcription of some common target genes. For example, both HMGA1 and HMGA2 proteins regulate the promoter activity of the IFN-ß and ERCC1 genes. However, it appears that there are some differences in binding properties and affinities of the HMGA1 and HMGA2 proteins to the promoters of these genes. For example, HMGA2 appears to have a higher affinity for the ERCC1 gene in comparison to HMGA1 (32) . Other examples include IL-2 and IL-2Rß where HMGA1 has a higher affinity than HMGA2 (68) and IL-15 and IL-15R where HMGA2 has a higher affinity than HMGA1 (69). However, HMGA1 and HMGA2 also show differences in target gene selection. The BRCA1 gene, for example, is negatively regulated by HMGA1 and not by HMGA2 (70) . It was long believed that the HMGA1a and HMGA1b proteins would be biologically interchangeable, since the only difference between them is an internal deletion of 11 amino acids. However, more and more reports now demonstrate that there are in fact some differences between the two isoforms. Cmarik et al undertook a study in which they compared the levels of the two proteins in response to treatment of cells with the tumor promoting agent 12-O-tetradecanoylphorbol acetate (TPA). With their experiments, they were able to show that differential induction of HMGA1b, relative to HMGA1a, was important for the TPA-induced neoplastic transformation process (71) . Direct confirmation that HMGA1a and -A1b could indeed have different functions in vivo, also came from studies performed by Reeves et al. These experiments showed that tetracycline-regulated induction of HMGA1b in the non-metastatic MCF-7 mammary epithelial cells caused them to progress much more rapidly to a metastatic and highly malignant phenotype than did induced overexpression of HMGA1a. Furthermore, microarray studies comparing the gene expression profile in HMGA1a to that in HMGA1b overexpressing MCF-7 cells, clearly illustrated that the two isoforms differentially regulate specific genes in the transgenic MCF-7 cells (72) .
Since the amino acid composition of the DNA binding domains of the HMGA1 and HMGA2 proteins is nearly identical, the difference in target gene selection and/or binding affinities must most likely be explained by other regions of these proteins. It appears that one reason for their abililty to exert dissimilar functions is due to the different spacing of the AT-hooks along the protein molecules (Fig. 4) . This allows the different HMGA proteins to establish interactions with alternatively spaced AT-rich DNA stretches. From studies concerning possible differential in vivo modifications, it is also clear that HMGA1a and HMGA1b proteins might participate in different cellular processes based on their unique collections of in vivo post-translational modifications (56, 64) . In the next section it will become clear that these differences in target gene selection and/or binding affinity by the HMGA family members result in different cellular functions.
Cellular functions of the HMGA proteins
HMGA proteins in growth and differentiation. In general, the development of an organism consists of a few fundamental aspects. One of them is 'growth'. Classical genetic studies in mice have isolated four viable, spontaneous mutants disrupted in growth, leading to dwarfism (73) . Three of the four phenotypes could be explained by aberrations in the growth hormone insulin-like growth factor endocrine pathway. One of the phenotypes, called 'pygmy', appeared to be the result of a major disruption at a particular spot in the genome. The gene affected was identified as being the hmga2 gene (74) . The same scientists then generated a mouse null mutant of hmga2 to exclude the possibility that another gene might be responsible for the pygmy phenotype. Homozygous hmga2 -/-mice revealed the classical features of the pygmy phenotype including reduced birth weight, craniofacial defects (shortened head), and an adult body weight of approximately 40% of that of wild-type littermates (74, 75) . Further insight into the function of hmga2 was obtained by studying the growth characteristics of fibroblasts derived from hmga2 null mice. These fibroblasts showed a 4-fold less proliferation capacity compared to fibroblasts derived from wild-type mice (74, 75) . In 12.5-dpc embryos of both hmga2-deficient mice strains (pygmy and hmga2 -/-mice), it was found that the insulin-like growth factor II mRNA binding protein 2 (Imp2) gene was significantly down-regulated as compared to wild-type embryos (76) . Imp2 is an mRNA-binding protein which is involved in temporal and spatial control of gene expression at the level of mRNA rather than at the level of gene transcription. In this regard, it is tempting to speculate that the effect of hmga2 on cell proliferation during embryonic development involves imp2. More recently it was shown by our group that Imp2 is regulated by HMGA2 via an intronic regulatory element, in cooperation with NF-κB (77) .
These data, together with the observation that HMGA proteins are rapidly induced in quiescent normal cells following exposure to growth stimulatory factors and thus classifying the HMGA proteins as 'delayed early response genes' (78), clearly suggest involvement of the HMGA genes in growth regulation.
In situ hybridization analysis of both hmga1 and hmga2 showed a very similar time course of expression during fetal life. High levels of expression are observed in nearly all tissues in the earliest stages analyzed: 8.5 dpc for hmga1 (79) and 9.5 dpc for hmga2 (80) . During later stages of development, the expression patterns become more restricted to specific organs and tissues. For hmga1, the expression is confined to tissues of ectodermal, mesodermal and endodermal origin. Hmga2 expression on the other hand, is mainly confined to mesodermal-derived tissues. At stages later than 15.5 dpc, Northern blot analysis showed low expression of hmga1, and no detectable expression of hmga2 (74, 81) . Hmga1 expression is observed at low levels in adult tissues of both human and mice (79) , while hmga2 expression is very low if detectable at all (82) .
Another aspect of fundamental importance for embryonic development is the establishment of the correct nature of cell types -or 'differentiation'. It appears that while hmga2 is mainly considered to be engaged in growth, hmga1 is more than a proliferation factor alone. For example, hmga1 is expressed in the cortical plate of the telencephalon and the spinal cord at 17.5 dpc. These tissues are composed mainly of differentiated, non-dividing cells. Hmga1 also shows a dramatically decreased expression during mouse teratocarcinoma differentiation (83) and an increased expression as cells dedifferentiate due to the expression of v-mos or v-Ras oncogenes (84) . Furthermore, hmga1 has been shown to exert a negative effect on the proliferation of adipocytic 3T3-L1 cells and a positive effect on differentiation of these cells (85) . The mouse pre-adipocyte 3T3-L1 cell line is a well characterized differentiation model. After hormonal stimulation, the 3T3-L1 cells can differentiate into adipocytes (86) . The hmga1 proteins seem to exert this role in adipocytic differentiation, in part, by physically interacting with C/EBP proteins, hereby functionally cooperating in their transcriptional activity. The function of C/EBP proteins is required to trigger the expression of adipocyte-specific genes. Conversely, hmga2 has a role in the proliferation step which precedes -and also is required forthe later phases of adipocyte differentiation (87) .
In an attempt to clarify the role of hmga1 proteins in embryonic development, Battista et al used ES cells carrying disruption of one or both alleles of the hmga1 gene. It appeared that hmga1 proteins are involved in different hematopoietic lineage commitment checkpoints. In hmga1 -/-embryoid bodies (EBs), myeloid differentiation was shown to be impaired, while megakaryocytic and erythroid differentiation was shown to be increased (88) . Hmga1 proteins were also shown to play a role in determining the fate of the lymphoid cell common precursor: the number of T-cell precursors was greatly reduced in hmga1 -/-cells, whereas the number of B-cell precursors was increased. Later, they showed that hmga1 down-regulates recombination activating gene 2 (RAG2), which is a key regulator of lymphoid differentiation, by directly inhibiting its promoter activity. They hereby suggest an additional mechanism for the modulation of lymphopoiesis by hmga1 proteins (89) .
Another group showed that both hmga1 alleles are required for normal sperm development in mice (90) . Hmga1 proteins are also shown to have a critical role in heart development and growth, since hmga1-null mice show cardiac hypertrophy due to the direct role of hmga1 on cardiomyocytic cell growth regulation (91).
Recently, it was proposed that the hmga2 protein could also be involved in differentiation, namely in skeletal muscle differentiation of embryonic stem cells (92) .
Together, these data strongly support a role for the HMGA proteins in the regulation of growth and differentiation, two fundamental aspects of development. Furthermore, it is clear that the HMGA proteins exert different biological roles. The hmga2 -/-mouse for example shows a pygmy-phenotype which is not compensated for by the hmga1 proteins. In fact, hmga1 expression was not altered in the pygmy-mouse in comparison to wild-type mice (74) . In addition, the hmga1 -/-mouse shows a different phenotype than that of the hmga2 -/-mouse: the former ones develop cardiac hypertrophy, myelo-lymphoproliferative disorders and diabetes (91, 93) .
HMGA proteins in tumors
Overexpression of the HMGA proteins in tumors. As mentioned above, HMGA1 and HMGA2 are hardly detectable in adult human tissues. The same holds true for hmga1 and hmga2 in mouse tissues. There are, however, some exceptions to the general repression of these genes in adult tissues. For example, there is a burst of synthesis of the HMGA1a protein during the immune response [(94,95) ; also see above] and in photoreceptor cells a constitutive expression of the HMGA1 proteins is observed (96) . The most studied and remarkable observation, however, is that there is a generalized derepression of HMGA1 and often HMGA2 expression in neoplastic cells.
Overexpression of members of the HMGA family, in particular of HMGA1, was first observed in HeLa cells (7) and in cultured rat thyroid cells transformed by viral oncogenes (84) . HMGA1 expression was also shown to correlate with the progressive transformation of rat prostate cells (97) and mouse mammary epithelial cells (98) . In humans, overexpression of HMGA1 has been described in a large number of different types of cancer, all being malignant epithelial tumors. These include those of the following organs: prostate (99,100), colorectum (101) (102) (103) , lung (104), breast (105, 106) , pancreas (107, 108) , and thyroid (109) . In all these tumors, increasing concentrations of HMGA1 proteins are correlated with increasing degrees of malignancy or metastatic potential.
HMGA2 overexpression is also observed in various malignant tumor types: breast cancer (110), sarcomas (111), pancreas (112), oral squamous cell carcinomas (113) , and non-small cell lung cancer (114) . Furthermore, in welldifferentiated liposarcomas (WD-LPS), it was shown that there exists a positive and statistically significant correlation between HMGA2 and IMP2 gene expression (77). As stated above, Imp2 was identified as an HMGA2 target gene in 12.5 dpc embryos of two hmga2-deficient mice strains. In contrast, Brants et al showed that HMGA2Tr, which is frequently expressed in benign solid tumors (also see below), exerts a negative effect on Imp2 gene expression (76) . These observations point towards the potential significance of a deregulated HMGA2-IMP2 pathway in this kind of tumors.
The role of HMGA1 and HMGA2 overexpression in tumor development is further supported by different observations. Overexpression of HMGA1 and HMGA2 proteins led to transformation of Rat1a fibroblasts and human lymphoid CB33 cells (115, 116) . Quite recently, hmga1a, hmga1b and hmga2 transgenic mice were developed. Both hmga1b and hmga2 transgenic mice develop mixed growth hormone/ prolactin cell pituitary adenomas (69, 117) . However, the HMGA1 gene has not yet been implicated in the generation of human pituitary adenomas. On the contrary, the HMGA2 gene is found to be amplified in human prolactinomas, and this is associated with HMGA2 overexpression (118) . A crucial step in the onset of pituitary adenomas in hmga2 transgenic mice, and probably also in humans, is E2F1 activation (119, 120) . The transcriptional activity of the E2F family of transcription factors is crucial for the expression of several genes required to enter the S-phase of the cell cycle (121). Hmga2 acts by displacing HDAC1 from E2F1 target promoters, hereby recruiting histone acetylases which first acetylate the histones -relieving transcriptional repressionand then also acetylate E2F1 causing its stabilization (119, 120) . This model provides a very nice example of the mode of action of HMGA proteins to activate transcription and of the effect of post-translational modifications on their function (also see above). Hmga1a transgenic mice develop aggressive, highly penetrant lymphoid malignancy and HMGA1a is also overexpressed in human lymphoid leukemia (122, 123) . In addition to lymphoid malignancy, Hmga1a transgenic mice develop uterine tumors, which resemble human uterine adenosarcomas (124) . In most high-grade, but not in benign or most low-grade human uterine adenosarcomas, significant overexpression of HMGA1a is detected (124) . HMGA1a could thus serve as a useful marker for such aggressive uterine tumors.
Rearrangements of HMGA1 and HMGA2 genes in human benign tumors.
Tumor type-specific chromosomal rearrangements resulting in the formation of a specific fusion protein have been shown to be causally related to the development of many tumor types. Rearrangements in the HMGA genes are found in various benign mesenchymal tumors such as lipomas (125, 126) , pleiomorphic adenomas of the salivary glands (127) , uterine leiomyomas (128) (129) (130) , angiomyxomas (131), pulmonary chondroid hamartomas (130, 132) , and endometrial polyps (133) (134) (135) . Since most translocations involve the HMGA2 gene, the focus of this section will mainly be on HMGA2.
For HMGA2, these translocations involve chromosome region 12q13-15. The chromosome breakpoints often occur in the large third intron of HMGA2, which separates the DNA-binding domains from the acidic domain (see above). The translocation thus results in a disrupted HMGA2 gene wherein the AT-hooks of HMGA2 become separated from the acidic tail and become fused to a variety of ectopic sequences. In lipomas, the preferred translocation partner was shown to be located in chromosome region 3q27-28. In this region, the LIM-domain containing lipoma preferred partner (LPP) was identified (136) . In uterine leiomyomas, the recombinational repair gene RAD51B on chromosome 14q23-24 was identified as the preferential translocation partner of HMGA2 (137) . Some of the fusions involving HMGA2 occur in frame. In that case, the fusion partner could have a specific role in tumor formation, for instance in the case of the HMGA2-LPP fusion. It is noteworthy that the HMGA2-LPP fusion protein is not specific for lipomas, but also has been detected in pulmonary chondroid hamartomas (138) .
On the other hand, it is possible that the in frame fusion partner contributes only a few amino acids to the chimeric protein. The mitochondrial dehydrogenase gene (ALDH2), identified as a fusion partner of HMGA2 in a primary uterine leiomyoma, for example, contributes less than 10 amino acids to the fusion protein (139) . However, most of the fusions occur out of frame, and mostly a stop codon is encountered quickly so that only a few amino acids are added to the AT-hooks of HMGA2. An example is the lumican encoding gene (LUM), which is observed as a translocation partner of HMGA2 in an osteosarcoma-derived cell line (140) . All this suggests that the minimal requirement for tumorigenesis would be HMGA2 activation due to rearrangements that leave intact at least exons 1, 2 and 3, which encode for the AT-hook domains. In conclusion, translocations involving 12q13-15 often result in the formation of a truncated form of HMGA2, called HMGA2Tr, mainly consisting of the three DNA-binding domains.
Rearrangements in other regions than the large third intron have also been described. For example, in uterine leiomyomas, breakpoints upstream and downstream of the HMGA2 gene have been identified (141, 142) . The existence of breakpoints outside the gene could mean that transcriptional activation, as a consequence of its juxtaposition to enhancer elements in the translocation partner, is sufficient to induce tumor development.
Recent, new insights indicate that the removal of the 3' untranslated region (UTR) by chromosomal rearrangements may contribute to tumorigenesis. The 3' UTR contains multiple putative let-7 binding sites. Let-7 was one of the first identified micro-RNA (miRNA) genes, the expression of which seems to be developmentally regulated in both human (143) and mice (144) . Intriguingly, the expression of let-7 during development is inversely correlated with that of HMGA2, leading to the hypothesis that let-7 might act as a repressor of HMGA2. In addition, let-7 seems to be deregulated in uterine leiomyomas, in which HMGA2 translocations -resulting in the removal of the 3' UTR -are often observed. This type of post-transcriptional regulation by miRNAs, as well as its functional importance is described below in further detail.
The role of HMGA2 disruption as the initiating event in tumor development is, however, somewhat controversial (145) . Still, there is evidence supporting a causal role for the HMGA2 protein in the onset of benign neoplasia. In vitro experiments show that both HMGA2Tr and HMGA2/LPP are able to induce neoplastic transformation of NIH-3T3 fibroblasts (146) . In addition, Crombez et al showed that in a number of lipomas, HMGA2/LPP and HMGA2 are coexpressed, and that HMGA2 augments the transactivation functions of HMGA2/LPP (147) . These results support the concept that the transactivation functions of the HMGA2/ LPP transcription factor contribute to lipomagenesis. In vivo evidence includes observations in both mouse and human. Hmga2Tr transgenic mice developed by the group of Fusco present gigantism, associated with lipomatosis (148) . They also develop natural killer NK-T/NK cell lymphomas, which are very similar to the NK-T/NK cell lymphomas seen in hmga1b transgenic mice. The induction of NK-T/NK cell lymphomas in these transgenic mice is probably due to overexpression of IL-2 and IL-15, which are shown to be target genes of HMGA2, HMGA2Tr and HMGA1 (68, 69) . Hmga2Tr transgenic mice made independently by Arlotta et al develop adiposity and display an abnormal high incidence of lipomas (149) . In 2005, an 8-year-old male was described with a de novo pericentric chromosomal inversion of chromosome 12, resulting in the expression of a truncated form of HMGA2 only containing the DNA-binding AT-hooks. The patient showed somatic overgrowth, multiple lipomas, advanced endochondral bone and dental aging and a cerebellar tumor (150) . Together, these findings seem to suggest that the DNA-binding domains of HMGA2 are sufficient to predispose to various benign neoplasms.
HMGA2 rearrangements have not only been identified in benign neoplasms, but also in several types of malignant mesenchymal tumors such as well-differentiated liposarcomas (151) , and inflammatory myofibroblastic tumors (152) .
For HMGA1, rearrangements involve chromosomal region 6p21.3. Breakpoints in most tumors seem to be located 3' of HMGA1 (130), although breakpoints located 5' (130) or intragenic (153, 154) have also been reported.
HMGA proteins in other critical diseases.
The proper control of constitutive and inducible gene expression is critical for the physiologic homeostasis of a complex organism, like for example, the human body. Abnormal regulation of gene expression is therefore likely to contribute to a pathophysiologic process for many diseases. The manner in which genes are regulated may for instance determine the aggressiveness of a disease or the ability of a patient to survive a critical illness. This not only holds true for cancer, as described above, but also for other critical illnesses. Architectural transcription factors, such as the HMGA proteins, thus constitute interesting targets in disease in which such genes are expressed inappropriately.
As a first example, HMGA proteins are known to contribute to the regulation of many genes that are involved in the inflammatory response. HMGA1 regulates genes which contribute to the proliferation, differentiation, antigen presentation, and recruitment of inflammatory cells, as well as to cytokine and inflammatory mediator production that participate to the inflammatory response. These genes include: nitric oxide synthase 2 IFN-ß (reviewed in ref. 39) . When the host's immune cells -including macrophages -are activated, they release pro-inflammatory cytokines, such as IL-1ß and tumor necrosis factor-α (TNF-α). Uncontrolled release of these proinflammatory cytokines would lead to hypotension and shock. Indeed, an overpowering inflammatory response, owing to severe infection, results in sepsis. Since HMGA1 is known to contribute to the regulation of a number of genes involved in the inflammatory response, and since many of the signals responsible for gene expression involve an inflammatory response, it is believed that HMGA1 proteins could have a potential role in the pathophysiology of sepsis (39) . Based on several pieces of information, it has also been hypothesised that impairment of HMGA1 function might be responsible for some cases of human immunodeficiency: i) hmga1-null mice develop B-cell lymphomas (91) , ii) hmga1 overexpressing mice develop T-cell lymphomas (69), iii) hmga1 has been shown to regulate RAG2 expression in a negative fashion (89) , iv) inactivating mutations in RAG2 are responsible for the 'Omen syndrome', in which no circulating mature B-cells are found, while a large number of poorly functional T-lymphocytes could be detected (155) , and v) overexpression of RAG proteins may contribute to some cases of human immunodeficiency (156) and lymphocytic leukemia.
(NOS2), cyclo-oxygenase 2 (Cox-2), E-selectin, Immunoglobulin E (IgE), Interleukin 4 (IL-4), IL-2, granulocyte macrophage-colony stimulating factor (GM-CSF), and
Another example of a critical illness with an important role for HMGA1 is type 2 diabetes mellitus. Type 2 diabetes mellitus is a widespread disease, affecting millions of people worldwide. The cause of this metabolic disorder is largely unknown. A few years ago, four type 2 diabetes patients were reported with a markedly reduced expression of HMGA1. This appeared to negatively affect insulin receptor expression and function in insulin target cells and tissues. This defect in HMGA1 expression may have induced the insulin resistance and type 2 diabetes in these patients (93) . It was already shown before that HMGA1 is required for proper INSR gene transcription (157, 158) . The same group also developed hmga1 knock-out mice. These mice showed a considerably decreased insulin receptor expression in the major targets of insulin action, largely impaired insulin signalling, and severely reduced insulin secretion, causing a phenotype characteristic of human type 2 diabetes (93) .
Besides a diabetes phenotype, hmga1 +/ -and hmga1 -/-mice also develop cardiac hypertrophy. This is due to the role of hmga1 on cardiomyocytic cell growth regulation, via increased levels of class II calcium/calmodulin-dependent protein kinase (CaMKII) -which is normally repressed by hmga1 (91).
Regulation of HMGA expression
HMGA gene expression can be regulated in response to a large array of cellular stimuli. Many growth factors are able to induce HMGA gene expression through mechanisms common to the delayed early reponse of gene expression (reviewed in ref. 159) . They are thus induced after a delay of a few hours after growth factor addition and require new protein synthesis (78) . HMGA1 has also been shown to be induced by the tumor-promoting agent 12-O-tetradecanoyl phorbol-13-acetate (TPA) (160) .
Moreover, HMGA expression can be repressed by activation of a differentiation program. For example, in neuroblastoma and in embryonic carcinoma cells, HMGA1/2 expression can be repressed by retinoic acid (87, 161, 162) . In addition, IL-1ß, endotoxin and IFN-ß -all mediators of the inflammation program -can induce HMGA1 expression. As mentioned above, the condition most consistently associated with deregulated HMGA1/2 expression, is cellular transformation. Nevertheless, the question of how HMGA1 and HMGA2 expression is deregulated in tumors is not clear. In what follows, possible mechanisms of HMGA1/2 deregulation in cancer will be discussed.
Transcriptional (de)regulation of HMGA1.
Transcriptional deregulation is probably a major mechanism involved in the aberrant expression of HMGA1 in tumors. However, little is known about transcriptional regulation of HMGA1 in both normal cells as well as in tumor cells. A partial explanation for this comes from the extremely complex structure and transcriptional regulation of both the mouse and human HMGA1 gene. It comprises four different transcription start sites, of which the first two are considered to be the major ones (160) .
Only a few cis-acting elements have been characterized on the HMGA1 promoter. A schematic overview of the human HMGA1 promoter and the transcription factor binding sites for which an involvement in HMGA1 regulation is shown, is depicted in Fig. 5 . An AP1-binding site located immediately before start site 2 of the human HMGA1 promoter was shown to be required for TPA induction in K562 cells (160) . Furthermore, hmga1 is a direct target of AP1 in Rat1a cells via binding of c-Jun to an AP1-binding site located at -1337 bp of the mouse hmga1 promoter (163) . An E-box located at -1353 and -1337 bp of the human and mouse HMGA1 promoter respectively, is essential for c-myc-dependent induction of HMGA1 expression in Burkitt's lymphoma cell lines and HEK293 cells (116) . In addition, HMGA1 expression is also associated with MYCN amplification in primary human neuroblastomas. HMGA1 appears to be a direct MYCN transcriptional target, wherein MYCN mediates HMGA1 transactivation by multiple cis-acting elements located near the first three transcription start sites (162) .
The work done by Wood et al, indicates that activation of HMGA1 expression by the c-myc oncogene is essential for the appearance of the fully transformed Burkitt's lymphoma phenotype. Indeed, inactivation of HMGA1 expression reversed the transformed phenotype (116) . Still, it is clear that c-myc-induced HMGA1 expression cannot represent a ubiquitous means of reactivating its expression. Indeed, we reported recently that the AP1-binding site before start site 2 (in the so-called Proximal Regulatory Region 2), together with an SP1-binding site before start site 1 (in Proximal Regulatory Region 1) are important for basal transcription of the HMGA1 gene (164) . In addition, we have shown that the HMGA1 promoter is strongly inducible by oncogenic Ras, via a distal regulatory region (Fig. 5 ). An AP1-binding site and three SP1-like-binding sites are responsible for this inducible activity. The E-box located at -1353 bp was not of importance for the oncogenic Ras-induced expression. An even more convincing finding for a role of oncogenic Ras in the regulation of HMGA1 in cancers, was the discovery that HMGA1 upregulation in the HCT116 colon cancer cell line is abolished when the mutated Ras allele is removed from these cells. These data clearly show that it is thus more than likely that not only c-myc, but also other oncogenic pathways directly target HMGA1 expression in neoplasia.
Further detailed analysis of the HMGA1 promoter could help to identify other cis-acting elements and trans-acting factors responsible for HMGA1 deregulation in so many different types of cancer.
Regulation of HMGA2 expression. Experiments performed by Ayoubi et al demonstrated that the HMGA2 promoter also contains multiple transcription initiation sites, which are differentially utilized. In addition, they show that HMGA2 5'-flanking sequences had constitutive promoter activity in cell lines which express high levels of HMGA2, and in cell lines which do not express HMGA2 (87) . It is thus possible that HMGA2 is regulated by negative regulatory elements, which were not included in the described experiments, and/or that HMGA2 could be regulated at the post-transcriptional level.
Concerning the latter, very recent, new insights have emerged. It was always presumed that the loss of its C-terminal region, resulting from for example chromosomal translocations concerning the HMGA2 gene, would be the cause of oncogenic transformation. However, chromosomal rearrangements in some tumors leave the ORF intact, but instead disrupt the 3' UTR. This is associated with overexpression of the wild-type HMGA2 protein (125, 127) . In addition, luciferase reporter experiments in which large portions of the hmga2 3' UTR are used, show repression of luciferase activity (165) . Moreover, transgenic mice overexpressing wild-type hmga2 have similar phenotypes as those expressing hmga2Tr: both develop abdominal lipomatosis, lymphomas, pituitary adenomas, and lung adenomas (68, 117, 148) . It is, therefore, now believed that transformation by HMGA2 might be caused by the loss of repressive elements in its 3' UTR. Within the last few years, miRNAs have emerged as important regulators of both transcriptional and post-transcriptional gene silencing. miRNAs are RNAs of approximately 22 nucleotides in length that typically bind to the 3' UTRs of specific mRNA CLEYNEN and VAN DE VEN: THE HMGA PROTEINS: A MYRIAD OF FUNCTIONS 300 Figure 5 . Schematic overview of the HMGA1 promoter. PRR1, proximal regulatory region 1; PRR2, proximal regulatory region 2; TS1, transcriptional start site 1; TS2, transcriptional start site 2; restriction enzyme recognition sites used to make 5'-deletion constructs of the HMGA1 promoter (italics): Sf (SfiI), Bb (BbrPI), Bs (Bsu36I), As (AscI), M (MluNI), E (EcoRI), X (XhoI), Sm (SmaI), A (ApaI), P (PacI) and S (SspI). A detailed description of how the different regions were defined, can be found in ref. 164 . The transcription factor binding sites, for which an involvement in HMGA1 regulation is shown, are indicated.
targets and repress their expression at the post-transcriptional level. Aberrant miRNA expression can contribute to tumorigenesis. Recently, two independent groups showed that the HMGA2 transcript can be regulated by let-7 miRNA. Disruption of the let-7 repression of HMGA2, by inhibiting let-7 using a 2'-O-methyl antisense oligonucleotide against let-7, enhances cell proliferation in H1299 (166) cells and causes transformation in NIH-3T3 cells (167) . Let-7 miRNA thus might act as a repressor of HMGA2. In conclusion, losing miRNA-directed repression of an oncogene could provide a mechanism for tumorigenesis. This mechanism could also apply for HMGA1, since numerous HMGA1 transcripts with a truncated 3' UTR have been reported in tumors (130, 168) .
Conclusion
Together, these observations establish an extremely important role for the HMGA proteins in cancer and other diseases. It is, therefore, of crucial importance to have insight in the mechanism(s) behind the elevated regulation of expression of HMGA1, but also in the exact role played by the HMGA proteins in the development of a variety of tumors and other diseases.
In an era where diseases such as cancer, diabetes, and obesity are prevailing, proteins like those of the HMGA family and the complex context in which they operate, will certainly be of interest to study in the context of pharmacogenomics. Pharmacogenomics holds the promise that drugs might one day be custom-made for individuals and adapted to each person's own genetic make-up. The anticipated benefit of pharmacogenomics is that pharmaceutical companies will be able to create drugs interfering specifically with the proteins, enzymes, or RNA molecules associated with genes which are linked to diseases. This will profoundly affect drug discovery strategies and enable drug makers to develop therapeutic strategies more specifically targeted to a particular disease of an individual or a group of individuals.
